Cargando…
Clinical Relevance of Serum Galactose Deficient IgA1 in Patients with IgA Nephropathy
New biomarkers of IgA nephropathy (IgAN) are needed for non-invasive diagnosis and appropriate treatment. There is emerging evidence that galactose deficient IgA1 (Gd-IgA1) is a pivotal molecule in the pathogenesis of IgAN. However, few studies have investigated the role of Gd-IgA1 as a biomarker in...
Autores principales: | Kim, Jin Sug, Hwang, Hyeon Seok, Lee, Sang Ho, Kim, Yang Gyun, Moon, Ju-Young, Kong, Ji Yoon, Jeong, Kyung Hwan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694202/ https://www.ncbi.nlm.nih.gov/pubmed/33158064 http://dx.doi.org/10.3390/jcm9113549 |
Ejemplares similares
-
Galactose-Deficient IgA1 as a Candidate Urinary Marker of IgA Nephropathy
por: Fukao, Yusuke, et al.
Publicado: (2022) -
Serum galactose-deficient-IgA1 and IgG autoantibodies correlate in patients with IgA nephropathy
por: Placzek, William J., et al.
Publicado: (2018) -
Effect of Immunosuppressive Drugs on the Changes of Serum Galactose-Deficient IgA1 in Patients with IgA Nephropathy
por: Kim, Min Jeong, et al.
Publicado: (2016) -
ELL2 Is Downregulated and Associated with Galactose-Deficient IgA1 in IgA Nephropathy
por: Liu, Youxia, et al.
Publicado: (2019) -
Serum Galactose-Deficient IgA1 Level Is Not Associated with Proteinuria in Children with IgA Nephropathy
por: Hastings, M. Colleen, et al.
Publicado: (2012)